

Resource Summary Report

Generated by [Kravitz](#) on Sep 10, 2026

GSE4271

RRID:SCR_003643

Type: Tool

Proper Citation

GSE4271 (RRID:SCR_003643)

Resource Information

URL: <http://ranchobiosciences.com/gse4271/>

Proper Citation: GSE4271 (RRID:SCR_003643)

Description: Curated data set from a study that investigated 77 primary high-grade astrocytomas and 23 matched recurrences so that changes in gene expression related to both survival and disease progression can be identified. Samples in the study include WHO grade III and IV astrocytomas with a wide range of survival times.

Abbreviations: GSE4271

Resource Type: data or information resource, data set

Keywords: adult human, brain, gene expression

Related Condition: Cancer, Astrocytoma

Availability: Free, Public

Resource Name: GSE4271

Resource ID: SCR_003643

Alternate IDs: nlx_157794

Record Creation Time: 20220129T080220+0000

Record Last Update: 20260905T133324+0000

Ratings and Alerts

No rating or validation information has been found for GSE4271.

No alerts have been found for GSE4271.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 62 mentions in open access literature.

Listed below are recent publications. The full list is available at [Kravitz](#) .

Duffy JT, et al. (2026) Fully Humanized Bispecific T Cell Engager Shows Potent Activity in Central Nervous System and Peripheral Tumors. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(35), e22391.

Chen Z, et al. (2026) Phase Separation-Mediated SRF/P54nrb Transcription Complex Shapes the Vasculature Microenvironment via Upregulating OLFML3 in Glioblastoma. *MedComm*, 7(6), e70759.

Xu Y, et al. (2025) Modulation of tumor inflammatory signaling and drug sensitivity by CMTM4. *The EMBO journal*, 44(6), 1866.

Liu R, et al. (2024) Toxicity profiles of immune checkpoint inhibitors in nervous system cancer: a comprehensive disproportionality analysis using FDA adverse event reporting system. *Clinical and experimental medicine*, 24(1), 216.

Shen SH, et al. (2024) The GGCT and REST positive feedback loop promotes tumor growth in Glioma. *Translational oncology*, 49, 102083.

Lee J, et al. (2022) Differential dependency of human glioblastoma cells on vascular endothelial growth factor?A signaling via neuropilin?1. *International journal of oncology*, 61(4).

Zhou Z, et al. (2022) Single cell RNA sequencing reveals differentiation related genes with drawing implications in predicting prognosis and immunotherapy response in gliomas. *Scientific reports*, 12(1), 1872.

Serafim RB, et al. (2022) PIMREG expression level predicts glioblastoma patient survival and affects temozolomide resistance and DNA damage response. *Biochimica et biophysica acta. Molecular basis of disease*, 1868(6), 166382.

Zhou Z, et al. (2022) Characterization of aging tumor microenvironment with drawing implications in predicting the prognosis and immunotherapy response in low-grade gliomas. *Scientific reports*, 12(1), 5457.

Yoo KC, et al. (2022) Soluble ICAM-1 a Pivotal Communicator between Tumors and Macrophages, Promotes Mesenchymal Shift of Glioblastoma. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 9(2), e2102768.

Qing M, et al. (2021) Highly Expressed CYBRD1 Associated with Glioma Recurrence Regulates the Immune Response of Glioma Cells to Interferon. *Evidence-based complementary and alternative medicine : eCAM*, 2021, 2793222.

Chang Y, et al. (2021) A potentially effective drug for patients with recurrent glioma: sermorelin. *Annals of translational medicine*, 9(5), 406.

Zhao Y, et al. (2021) K-RAS Acts as a Critical Regulator of CD44 to Promote the Invasiveness and Stemness of GBM in Response to Ionizing Radiation. *International journal of molecular sciences*, 22(20).

Ye T, et al. (2021) Adaptor Protein Complex 1 Sigma 3 Is Highly Expressed in Glioma and Could Enhance Its Progression. *Computational and mathematical methods in medicine*, 2021, 5086236.

Yang B, et al. (2020) GNG5 is an unfavourable independent prognostic indicator of gliomas. *Journal of cellular and molecular medicine*, 24(21), 12873.

Shin SH, et al. (2020) Synthetic lethality by targeting the RUVBL1/2-TTT complex in mTORC1-hyperactive cancer cells. *Science advances*, 6(31), eaay9131.

Yang B, et al. (2020) Integrated Transcriptome Analyses and Experimental Verifications of Mesenchymal-Associated TNFRSF1A as a Diagnostic and Prognostic Biomarker in Gliomas. *Frontiers in oncology*, 10, 250.

Zeng WJ, et al. (2020) Aberrant ASPM expression mediated by transcriptional regulation of FoxM1 promotes the progression of gliomas. *Journal of cellular and molecular medicine*, 24(17), 9613.

Li ZH, et al. (2019) Astrocytoma progression scoring system based on the WHO 2016 criteria. *Scientific reports*, 9(1), 96.

Wu R, et al. (2019) Downregulation of KLF13 through DNMT1-mediated hypermethylation promotes glioma cell proliferation and invasion. *OncoTargets and therapy*, 12, 1509.